Related Experiment Videos
Angiotensin-converting enzyme inhibitors in left ventricular dysfunction
1Department of Medicine, Audie Murphy Veterans Administration Hospital, San Antonio, Texas 78284, USA.
Insights
Angiotensin-converting enzyme (ACE) inhibitors improve survival in heart failure patients by approximately 6 months and reduce hospitalizations. These life-prolonging drugs also benefit patients after myocardial infarction but remain underutilized by primary care providers.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Angiotensin-converting enzyme (ACE) inhibitors are established treatments for chronic congestive heart failure.
- Recent evidence supports their use in post-myocardial infarction patients.
- Underutilization persists due to provider confusion regarding optimal patient selection.
Purpose of the Study:
- To evaluate the impact of ACE inhibitors on morbidity and mortality in patients with chronic heart failure and acute myocardial infarction.
- To clarify which patient subgroups benefit most from ACE inhibitor therapy.
- To address the underutilization of ACE inhibitors in clinical practice.
Main Methods:
- Systematic review and evaluation of randomized controlled trials.
- Analysis of data on morbidity and mortality outcomes.
- Assessment of ACE inhibitors' effects on survival and hospital admissions.
Main Results:
- ACE inhibitors significantly improve survival in symptomatic congestive heart failure patients, offering an approximate 6-month survival benefit.
- In asymptomatic systolic dysfunction, ACE inhibitors reduce heart failure-related hospital admissions.
- All patients experiencing acute myocardial infarction show improved survival with ACE inhibitor use.
Conclusions:
- ACE inhibitors offer substantial survival benefits and reduce hospitalizations in various cardiovascular conditions.
- Despite robust evidence, clinician reluctance to prescribe ACE inhibitors necessitates improved education on patient risk stratification and timely initiation of therapy.
- Optimizing ACE inhibitor use can enhance patient quality of life and long-term outcomes.
Abstract:
Angiotensin-converting enzyme (ACE) inhibitors have been used for more than a decade in the treatment of chronic congestive heart failure. In recent years these agents have been used in patients who survived a myocardial infarction. However, primary care providers are often confused as to which patients would benefit the most, and as a result, these life-prolonging drugs are underutilized. The results of randomized controlled trials evaluating ACE inhibitors' effect on morbidity and mortality in patients with chronic congestive heart failure or acute myocardial infarction were evaluated. Angiotensin-converting enzyme inhibitors clearly improve survival in patients with symptomatic congestive heart failure. This survival benefit is approximately 6 months. In patients with asymptomatic systolic dysfunction, these agents also decrease the number of hospital admissions due to heart failure. Angiotensin-converting enzyme inhibitors also improve survival in all patients who experienced an acute myocardial infarction. With the plethora of evidence regarding the positive effects that this class of drugs has on the quality of life and survival of patients with systolic dysfunction, it is still unclear why clinicians are reluctant to use them more often. Primary care providers need to be educated on how to risk stratify patients to make this therapy more cost effective, and when these agents should be started.